Project Grant R03DE034489

Award Date 7/15/25
Completion Date 7/14/27
Dollars Obligated $308K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $483,360 to the University of California, San Diego (UCSD) to conduct research aimed at identifying new precision therapies for oral cancer. The key focus is to exploit vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry to disrupt immune evasive mechanisms and enhance the activity of anti-PD-1...
This $390,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The key products and services to be delivered include: Developing a high-throughput, single-cell co-culture system to isolate individual tumor-killing T cells and identify their T cell receptors (TCRs). Performing...
This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, provides $1,564,226 to Virginia Commonwealth University to investigate the role of FOSL1 super-enhancers in defining the functional properties of cisplatin-enriched cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC). The research aims to validate FOSL1 super-enhancers as a target for overcoming...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,403,398 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on precision imaging approaches for understanding the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer. The project aims to utilize advanced imaging techniques to investigate how the hybrid...
This Project Grant award of $229,440 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms driving differential responses to a novel radio-immunotherapy combination in preclinical models of head and neck squamous cell carcinoma (HNSCC) and pancreatic adenocarcinoma (PDAC). The research aims to elucidate how regulatory T cells mediate the divergent responses...
This federal Project Grant award of $429,000.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program. The grant supports research to determine the functional roles and mechanisms of the human microbiome and metabolome in the pathogenesis of oral squamous cell carcinoma (OSCC), a prevalent and lethal form of head and neck cancer. The research aims to 1) define OSCC-associated metagenomic and...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $249,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the University of Missouri System to develop a novel organopet assay for precision therapy of head and neck cancer. The key products and services to be delivered under this 3-year grant include: Establishing a high-throughput automated platform to generate patient-derived tumor organoids (tumoroids) that capture tumor...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $164,322 to the Regents of the University of Michigan to investigate the evolution of pro-tumoral myeloid cells during the initiation of oral cancer. The researchers will utilize a preclinical mouse model to study the transition from oral epithelial dysplasia to head and neck squamous cell carcinoma, with a focus on...

This $308,223 Project Grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) will support research at Stanford University to define how the gene ACTL6A regulates metabolic reprogramming in head and neck squamous cell carcinoma (HNSCC). The key objectives are to quantify energy production under varying ACTL6A expression levels, explore links between ACTL6A, mitochondrial activity, and cancer stem cell maintenance, and investigate new combination therapy approaches targeting HNSCC metabolism. This 2-year project aims to establish ACTL6A's role in regulating cancer cell metabolism and open new avenues for treating this deadly form of oral cancer.

Generated 8/5/25, 5:54 AM